Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery (MONET BRIDGE)

Inclusion Criteria: 1. Provide written informed consent before initiation of any study related procedures. 2. Be ≥ 18 years of age. 3. Have received any dose of a P2Y12 inhibitor (clopidogrel, ticlopidine, prasugrel, or ticagrelor) at any dose within at least 48 hours prior to randomization. 4. Patients undergoing non deferrable cardiac or non cardiac surgery which requires discontinuation of P2Y12 inhibitor due to a significant bleeding risk. Exclusion Criteria: 1. Confirmed of suspected pregnancy (if woman of child-bearing potential) or lactating females 2. Active bleeding with evident contraindications to DAPT 3. Patients requiring oral anticoagulant therapy 4. PCI within 1 month 5. Intracranial neoplasm or history of intracranial surgery 6. History of bleeding diathesis 7. Thrombocytopenia (platelet count of less than 100,000/µL) 8. Known International Normalized Ratio (INR) greater than 1.5 at screening. 9. Requirement for dialysis treatment (hemodialysis or peritoneal) 10. Estimated Glomeular filtration rate eGFR \<30 ml/min 11. Administration of abciximab within 24 hours of randomization or administration of eptifibitide or tirofiban within 12 hours of randomization 12. Plans to continue oral anticoagulant or P2Y12 inhibitors or cangrelor in the pre-operative period 13. Refusal to receive blood transfusion 14. Receipt of fibrinolytic therapy in the 12 hours preceding randomization 15. Allergy, hypersensitivity, or contraindication to cangrelor, mannitol, sorbitol, or microcrystalline cellulose 16. High likelihood of being unavailable for follow-up 17. Participation in other clinical research studies involving the evaluation of other investigational drugs or devices within 30 days of randomization 18. Any disease or condition which, in the judgment of the investigator, would place the patient at undue risk by being enrolled in the trial